FDA's Bulk Advertising Citations Continue: CSL Behring And Talecris Get Letters For Their Alpha1 Proteinase Inhibitors
This article was originally published in The Pink Sheet Daily
Executive Summary
Firms were making similar claims that their products can reduce "lung function decline."